赵, 丰 – page 3 – eisai china lnc.-开元游戏大厅app版本合集

 赵, 丰 – page 3 – eisai china lnc.-开元游戏大厅app版本合集

entries by

eisai submits marketing authorization application for lecanemab as treatment for early alzheimer’s disease in great britain

eisai co., ltd. and biogen inc. announced today that eisai has submitted a marketing authorization application (maa) for lecanemab, an investigational anti-amyloid beta (aβ) protofibril antibody, for the treatment of early alzheimer’s disease with confirmed amyloid pathology in the brain, to the uk medicines and healthcare products regulatory agency (mhra) in great britain. lecanemab has been designated by the mhra for the innovative licensing and access pathway (ilap).

health canada accepts new drug submission for lecanemab as treatment for early alzheimer’s disease

tokyo and cambridge, mass., may 16, 2023 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, “biogen”) announced today that health canada has accepted a new drug submission (nds) for lecanemab (brand name in the u.s.: leqembi™), an investigational anti-amyloid beta (aβ) protofibril* antibody, for the treatment of early alzheimer’s disease (mild cognitive impairment due to alzheimer’s disease (ad) and mild ad dementia) with confirmed amyloid pathology in the brain.

feng yanhui, president of eisai china, visited sinopharm holding henan

feng yanhui, president of eisai china, visited sinopharm holding henan co., ltd for business research, accompanied by li yunlong, vp of eisai china, zhao jianjun, director of north china access department, and xia ruiying, manger of north china access department in eisai china. chen zhanyu, vice president of sinopharm holding and chairman of sinopharm holding henan, zhang zhaohui, general manager of sinopharm holding henan, xu hai, deputy general manager of sinopharm holding global procurement and supply chain service center , li jie, assistant general manager of sinopharm holding henan, and yang fan, director of supply chain business development department of sinopharm holding received feng yanhui and her delegation.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a joint development agreement with bliss biopharmaceutical (hangzhou) co., ltd. (headquarters: zhejiang province, china, “blissbio”), for bb-1701, an antibody-drug conjugate (adc) with option rights for a strategic collaboration.

presentations explore aria with the use of antiplatelets or anticoagulants and isolated aria-h in patients from eisai’s lecanemab phase 3 confirmatory clarity ad study in early alzheimer’s disease

网站地图